# Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer

> **NCT07638501** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Eastern Hepatobiliary Surgery Hospital** · enrollment: 123 (estimated)

## Conditions studied

- Biliary Tract Cancer (BTC)

## Interventions

- **DRUG:** Sintilimab + GC
- **RADIATION:** SBRT 7Gy✖️5 QD

## Key facts

- **NCT ID:** NCT07638501
- **Lead sponsor:** Eastern Hepatobiliary Surgery Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-06-15
- **Final completion:** 2029-06-15
- **Target enrollment:** 123 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07638501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07638501, "Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07638501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*